Matches in Wikidata for { <http://www.wikidata.org/entity/Q88117804> ?p ?o ?g. }
- Q88117804 description "2018 nî lūn-bûn" @default.
- Q88117804 description "2018年の論文" @default.
- Q88117804 description "2018年学术文章" @default.
- Q88117804 description "2018年学术文章" @default.
- Q88117804 description "2018年学术文章" @default.
- Q88117804 description "2018年学术文章" @default.
- Q88117804 description "2018年学术文章" @default.
- Q88117804 description "2018年学术文章" @default.
- Q88117804 description "2018年學術文章" @default.
- Q88117804 description "2018年學術文章" @default.
- Q88117804 description "2018年學術文章" @default.
- Q88117804 description "2018年學術文章" @default.
- Q88117804 description "2018年學術文章" @default.
- Q88117804 description "2018년 논문" @default.
- Q88117804 description "article científic" @default.
- Q88117804 description "article scientific" @default.
- Q88117804 description "article scientifique" @default.
- Q88117804 description "articol științific" @default.
- Q88117804 description "articolo scientifico" @default.
- Q88117804 description "artigo científico" @default.
- Q88117804 description "artigo científico" @default.
- Q88117804 description "artigo científico" @default.
- Q88117804 description "artikel ilmiah" @default.
- Q88117804 description "artikull shkencor" @default.
- Q88117804 description "artikulong pang-agham" @default.
- Q88117804 description "artykuł naukowy" @default.
- Q88117804 description "artículo científico publicado en 2018" @default.
- Q88117804 description "artículu científicu" @default.
- Q88117804 description "bilimsel makale" @default.
- Q88117804 description "bài báo khoa học" @default.
- Q88117804 description "naučni članak" @default.
- Q88117804 description "scienca artikolo" @default.
- Q88117804 description "scientific article published on 21 March 2018" @default.
- Q88117804 description "scientific article published on 21 March 2018" @default.
- Q88117804 description "scientific article published on 21 March 2018" @default.
- Q88117804 description "teaduslik artikkel" @default.
- Q88117804 description "tieteellinen artikkeli" @default.
- Q88117804 description "tudományos cikk" @default.
- Q88117804 description "vedecký článok" @default.
- Q88117804 description "vetenskaplig artikel" @default.
- Q88117804 description "videnskabelig artikel udgivet 21. marts 2018" @default.
- Q88117804 description "vitenskapelig artikkel" @default.
- Q88117804 description "vitskapeleg artikkel" @default.
- Q88117804 description "vědecký článek" @default.
- Q88117804 description "wetenschappelijk artikel" @default.
- Q88117804 description "wissenschaftlicher Artikel" @default.
- Q88117804 description "επιστημονικό άρθρο" @default.
- Q88117804 description "мақолаи илмӣ" @default.
- Q88117804 description "наукова стаття, опублікована в березні 2018" @default.
- Q88117804 description "научна статия" @default.
- Q88117804 description "научная статья" @default.
- Q88117804 description "научни чланак" @default.
- Q88117804 description "научни чланак" @default.
- Q88117804 description "מאמר מדעי" @default.
- Q88117804 description "مقالة علمية نشرت في 21 مارس 2018" @default.
- Q88117804 description "২১ মার্চ ২০১৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q88117804 description "บทความทางวิทยาศาสตร์" @default.
- Q88117804 description "სამეცნიერო სტატია" @default.
- Q88117804 name "Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms" @default.
- Q88117804 name "Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms" @default.
- Q88117804 type Item @default.
- Q88117804 label "Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms" @default.
- Q88117804 label "Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms" @default.
- Q88117804 prefLabel "Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms" @default.
- Q88117804 prefLabel "Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms" @default.
- Q88117804 P1433 Q88117804-7B17CD5B-3095-4A36-80C5-9A990F9D62E3 @default.
- Q88117804 P1476 Q88117804-9C8C0A13-7571-442E-933B-415D8EC2BC15 @default.
- Q88117804 P2093 Q88117804-0FEF5B15-E53F-4299-B7CB-08BA24E30BA0 @default.
- Q88117804 P2093 Q88117804-12087895-FC71-48E6-AC4E-47BAD7877828 @default.
- Q88117804 P2093 Q88117804-27CCF29A-A757-4284-8DFD-6A2E143B39CB @default.
- Q88117804 P2093 Q88117804-27D9146A-A5E6-49A3-A3C1-9052BC6E8120 @default.
- Q88117804 P2093 Q88117804-6E0C0FDB-6A96-4841-9698-A4C3E87C9B1B @default.
- Q88117804 P2093 Q88117804-8E3A63A3-68D9-4A6B-860C-ED432BCCD0CA @default.
- Q88117804 P2093 Q88117804-CCD675FE-50E5-408C-9643-E72ADC8C32D3 @default.
- Q88117804 P304 Q88117804-30EDFCFF-4328-4D8F-A91A-0000F6333904 @default.
- Q88117804 P31 Q88117804-D11A5828-0ACA-4EBB-9CB7-992AA51745FA @default.
- Q88117804 P356 Q88117804-1841BF01-A318-4F00-9926-CA29CC0B78F2 @default.
- Q88117804 P433 Q88117804-6078AF10-09C7-4E74-B06D-331F895475D2 @default.
- Q88117804 P478 Q88117804-E3B6C062-BC0D-4A99-B431-94CE8055F1A7 @default.
- Q88117804 P577 Q88117804-D444A724-9514-4B7C-8A66-74D76D7E2882 @default.
- Q88117804 P698 Q88117804-040CB52B-C519-4A65-B48B-0865F1E34C64 @default.
- Q88117804 P921 Q88117804-FCBBB4E3-31A0-4980-8BC4-FE272D52180E @default.
- Q88117804 P356 10428194.2018.1452214 @default.
- Q88117804 P698 29561205 @default.
- Q88117804 P1433 Q6534493 @default.
- Q88117804 P1476 "Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms" @default.
- Q88117804 P2093 "Alix Baugier de Materre" @default.
- Q88117804 P2093 "Anne Besançon" @default.
- Q88117804 P2093 "Habib Ghnaya" @default.
- Q88117804 P2093 "Jonathan Farhi" @default.
- Q88117804 P2093 "Kamel Laribi" @default.
- Q88117804 P2093 "Mustapha Alani" @default.
- Q88117804 P2093 "Nathalie Denizon" @default.
- Q88117804 P304 "2711-2714" @default.
- Q88117804 P31 Q13442814 @default.
- Q88117804 P356 "10.1080/10428194.2018.1452214" @default.
- Q88117804 P433 "11" @default.
- Q88117804 P478 "59" @default.
- Q88117804 P577 "2018-03-21T00:00:00Z" @default.
- Q88117804 P698 "29561205" @default.